Cristiana Carniti

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi request reprint RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor
    Italia Bongarzone
    Department of Experimental Oncology, National Cancer Institute, Milan, Italy
    Tumori 89:550-2. 2003
  2. pmc The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease
    Cristiana Carniti
    Department of Experimental Oncology and Laboratories, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Am J Pathol 168:1262-75. 2006
  3. pmc Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
    Lucia Farina
    Division of Hematology Bone Marrow Transplantation, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milan, Italy
    Haematologica 94:654-62. 2009
  4. ncbi request reprint PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting
    Cristiana Carniti
    Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy
    Cancer Res 63:2234-43. 2003
  5. ncbi request reprint RET and NTRK1 proto-oncogenes in human diseases
    Luisella Alberti
    Operative Unit Molecular Mechanisms of Tumor Growth and Progression, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Cell Physiol 195:168-86. 2003
  6. ncbi request reprint Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease
    Elena Arighi
    Developmental Biology, Institute of Biomedicine, Biomedicum Helsinki, P O Box 63, University of Helsinki, Helsinki, Finland FIN 00014
    Mol Endocrinol 18:1004-17. 2004
  7. ncbi request reprint RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B
    Aaron N Cranston
    Cancer Research UK Department of Oncology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
    Cancer Res 66:10179-87. 2006
  8. pmc NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
    Annamaria Galietta
    Department of Clinical Medicine, University of Milano Bicocca, Monza, Italy
    Blood 110:2600-9. 2007

Collaborators

Detail Information

Publications8

  1. ncbi request reprint RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor
    Italia Bongarzone
    Department of Experimental Oncology, National Cancer Institute, Milan, Italy
    Tumori 89:550-2. 2003
    ..PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation...
  2. pmc The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease
    Cristiana Carniti
    Department of Experimental Oncology and Laboratories, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Am J Pathol 168:1262-75. 2006
    ..These mice represent an interesting model for studying new therapeutic approaches for the treatment of HSCR disease...
  3. pmc Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
    Lucia Farina
    Division of Hematology Bone Marrow Transplantation, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milan, Italy
    Haematologica 94:654-62. 2009
    ....
  4. ncbi request reprint PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting
    Cristiana Carniti
    Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy
    Cancer Res 63:2234-43. 2003
    ..The use of PP1, which therefore acts as a degradation-inducing factor, may represent a promising new strategy to selectively target RET oncogenic products for destruction and holds promise for future medullary thyroid cancer therapy...
  5. ncbi request reprint RET and NTRK1 proto-oncogenes in human diseases
    Luisella Alberti
    Operative Unit Molecular Mechanisms of Tumor Growth and Progression, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Cell Physiol 195:168-86. 2003
    ..In addition, we attempted to identify the correlations between the different genetic alterations and the related pathogenetic mechanisms...
  6. ncbi request reprint Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease
    Elena Arighi
    Developmental Biology, Institute of Biomedicine, Biomedicum Helsinki, P O Box 63, University of Helsinki, Helsinki, Finland FIN 00014
    Mol Endocrinol 18:1004-17. 2004
    ....
  7. ncbi request reprint RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B
    Aaron N Cranston
    Cancer Research UK Department of Oncology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
    Cancer Res 66:10179-87. 2006
    ..Our findings have implications both in the clinic and in the successful development of novel kinase-targeted anticancer drugs...
  8. pmc NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
    Annamaria Galietta
    Department of Clinical Medicine, University of Milano Bicocca, Monza, Italy
    Blood 110:2600-9. 2007
    ..These results identify PSF as a novel NPM/ALK-binding protein and substrate, and suggest that PSF function may be perturbed in NPM/ALK-transformed cells...